Related Experiment Video
Updated: May 14, 2026
09:41
Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
Published on: July 19, 2019
Opioid Signaling in Multiple Sclerosis: Emerging Targets for Repair
Renata Perlikowska1, Małgorzata Domowicz2, Agnieszka Śliwińska1
1Department of Nucleic Acid Biochemistry, Medical University of Lodz, Pomorska 251, 92-213 Lodz, Poland.
International Journal of Molecular Sciences
|May 13, 2026
Summary
Opioid signaling shows promise for multiple sclerosis (MS) by potentially reducing inflammation, aiding myelin repair, and protecting nerves. Further research is needed to explore its therapeutic benefits beyond current treatments.
Area of Science:
- Neuroimmunology
- Neurodegenerative Diseases
Background:
- Multiple sclerosis (MS) is a chronic CNS disorder involving inflammation, demyelination, and neurodegeneration.
- Current MS therapies primarily target inflammation, with limited effects on neurodegeneration and potential safety concerns.
Purpose of the Study:
- To explore the potential of opioid signaling as a novel therapeutic avenue for MS.
- To investigate opioid signaling's immunomodulatory, remyelinating, and neuroprotective effects in MS.
Main Methods:
- Review of emerging preclinical data on opioid signaling in MS.
- Analysis of evidence regarding opioid-mediated interventions and their effects on inflammatory activity, demyelination, and neuronal survival.
Main Results:
- Opioid signaling demonstrates potential for immunomodulation, remyelination, and neuroprotection in MS.
- Evidence suggests opioid-mediated interventions can reduce inflammation, attenuate demyelination, and enhance neuronal survival.
- Preclinical findings provide a rationale for investigating the opioid system in MS therapy.
Conclusions:
- Opioid signaling represents an underexplored therapeutic pathway for multiple sclerosis.
- Opioid-mediated interventions show promise as adjunctive or novel strategies for MS treatment.
- Further investigation is warranted to validate the therapeutic potential of the opioid system in MS.
Related Concept Videos
01:22Opioid Receptors: Overview
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2, D-Pen5]-enkephalin or DPDPE for...
01:25Analgesia and Pain Management
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...